CD94 Antibody Kit, anti-human, FITC, REAlease® from MILTENYI BIOTEC B.V. & Co. KG

Search, find, compare suppliers for CD94 Antibody Kit, anti-human, FITC, REAlease® products.

Edit 
Product NameCD94 Antibody Kit, anti-human, FITC, REAlease®
DescriptionCD94 Antibody Kit, anti-human, FITC, REAlease®. Clone REAL287 is an antibody fragment derived from the full CD94 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity. | Clone REAL287 recognizes CD94, an approximately 45 kDa, single-pass, type II transmembrane protein, which belongs to C-type lectin superfamily. CD94 associates covalently with NKG2 family members and forms disulfide bonded heterodimers. CD94-NKG2 receptors bind HLA-E, the non-classical MHC class Ib molecule. Depending on the associated NKG2 member, CD94-NKG2 heterodimer transmits either activating or inhibitory signal. For, e.g, via immunoreceptor tyrosine based-inhibitory motifs (ITIMs) containing NKG2A, CD94-NKG2A heterodimers inhibit NK cell cytotoxicity. Besides NK cells, expression of CD94-NKG2 heterodimers is also shown on NK-T cells and a small percentage of CD8 cells in mice, where the crosslinking of CD94-NKG2 was shown to reduce the level of spontaneous apoptosis. | The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.
Size100 tests
Concentration1:50
ApplicationsFlow cytometry
Other NamesKLRD1, Kp43
Gene, Accession, CAS #n/a
Catalog #130-122-724
Price$375
Order / More InfoCD94 Antibody Kit, anti-human, FITC, REAlease® from MILTENYI BIOTEC B.V. & Co. KG
Product Specific ReferencesBrooks, A. G. et al. (1997) NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J. Exp. Med. 185: 795-800. | Braud, V. M. et al. (1998) HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391 (6669): 795-799. | Gunturi, A. et al. (2003) Preferential survival of CD8 T and NK cells expressing high levels of CD94. J Immunol 170: 1737-1745. | Wolpert, F. et al. (2015) Interferon-β modulates the innate immune response against glioblastoma initiating cells. PLoS One 10 (10): e0139603. | Cante-Barrett, K. et al. (2017) Loss of CD44dim expression from early progenitor cells marks T-cell lineage commitment in the human thymus. Front Immunol 8: 32.
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197

macs@miltenyibiotec.de

https://www.miltenyibiotec.com

Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Products

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.